中國醫療集團(08225.HK)兩新藥獲GMP生產批准
中國醫療集團(08225.HK)公布,公司負責的臨床研究開發服務喜恩卡片劑(重酒石酸卡巴拉汀片劑),和重酒石酸卡巴拉汀原料藥,在今年獲得新藥批准後在今年6月5日獲得GMP生產批准,其中喜恩卡片是全球第一個上市的獨家片劑,國內第一家獲得該產品的生產證書,據悉另外兩家國產仿製膠囊尚未上市銷售。
集團將負責包括喜恩卡、優芝青在內利用RWS-THERAPY和CRCO平臺開展上市後真實世界臨床研究,相信這將對集團收入產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.